市場調查報告書
商品編碼
955871

肌少症:至2030年的流行病學預測

Sarcopenia - Epidemiology Forecast to 2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 60 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供世界主要7個國家(美國、德國、西班牙、義大利、法國、英國、日本)的肌少症的相關調查,提供疾病概要,各國流行病學,治療和管理,未滿足需求等資訊。

目錄

第1章 主要洞察

第2章 摘要整理

第3章 SWOT分析

第4章 市場概要

  • 市場佔有率:2017年的肌少症的分佈
  • 市場佔有率:2030年的肌少症的分佈

第5章 疾病的背景和概要

  • 簡介
  • 定義與分類
  • 原因
  • 危險因素
  • 病理生理學
  • 生物標記
  • 其他的病情的關聯性
  • 診斷

第6章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的肌少症的患病數
  • 前提條件與根據:主要7個國家

第7章 各國流行病學

  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第8章 治療和管理

  • 治療方針
  • 指南
    • EWGSOP指南
    • Asian Working Group for Sarcopenia (AWGS)
    • International Conference on Sarcopenia and Frailty Research (ICSFR)
  • 選擇性雄激素受體調製器(SARM)
  • 患者回復的路程

第9章 未滿足需求

第10章 附錄

  • 報告調查手法

第11章 DelveInsight的服務內容

第12章 免責聲明

第13章 關於DelveInsight

目錄
Product Code: DIEI0012

DelveInsight's 'Sarcopenia - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Sarcopeniaepidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Sarcopenia: Understanding

The DelveInsight's Sarcopenia epidemiology report gives a thorough understanding of the Sarcopenia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Sarcopenia in the US, Europe, and Japan. Moreover, the report covers the detailed information of the Sarcopenia epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective by DelveInsight:

This section encompassing Sarcopenia epidemiology provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Sarcopenia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Detailed Epidemiology Segmentation:

The Sarcopenia epidemiology covered in the report provides historical as well as forecasted Sarcopenia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Sarcopenia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Sarcopenia report and model provide an overview of the global trends of Sarcopenia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Sarcopenia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Sarcopenia.
  • The report provides the segmentation of the Sarcopenia epidemiology

Report Highlights::

  • 11-year Forecast of Sarcopenia Epidemiology
  • 7MM Coverage
  • Prevalent cases of Sarcopenia
  • Prevalence of Sarcopenia by gender

KOL - Views:

We interview KOLs and include SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered:

  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Sarcopenia?
  • What are the key findings pertaining to the Sarcopenia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Sarcopenia across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of Sarcopenia?
  • What are the currently available treatments of Sarcopenia?

Reasons to buy:

The Sarcopenia Epidemiology report will allow the user to:

  • Develop business strategies by understanding the trends shaping and driving the global Sarcopenia market.
  • Quantify patient populations in the global Sarcopenia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Sarcopenia therapeutics in each of the markets covered
  • Understand the magnitude of Sarcopenia population by its epidemiology
  • The Sarcopenia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments:

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1 Key Insights

2 Executive Summary of Sarcopenia

3 SWOT Analysis for Sarcopenia

4 Sarcopenia Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of Sarcopenia in 2017
  • 4.2 Market Share (%) Distribution of Sarcopenia in 2030

5 Disease Background and Overview

  • 5.1 Introduction
  • 5.2 Definition and classification
  • 5.3 Causes
  • 5.4 Risk factors
  • 5.5 Pathophysiology
  • 5.6 Biomarkers
  • 5.7 Relevance to other disease states
  • 5.8 Diagnosis

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 Total Prevalent Population of Sarcopenia in 7MM
  • 6.3 Assumption and Rationale: 7MM

7 Country Wise-Epidemiology of Sarcopenia

  • 7.1 The United States
    • 7.1.1 Prevalent cases of Sarcopenia in the United States
    • 7.1.2 Prevalence of Sarcopenia by Gender in the United States
  • 7.2 Germany
    • 7.2.1 Prevalent cases of Sarcopenia in Germany
    • 7.2.2 Prevalence of Sarcopenia by Gender in Germany
  • 7.3 France
    • 7.3.1 Prevalent cases of Sarcopenia in France
    • 7.3.2 Prevalence of Sarcopenia by Gender in France
  • 7.4 Italy
    • 7.4.1 Prevalent cases of Sarcopenia in Italy
    • 7.4.2 Prevalence of Sarcopenia by Gender in Italy
  • 7.5 Spain
    • 7.5.1 Prevalent cases of Sarcopenia in Spain
    • 7.5.2 Prevalence of Sarcopenia by Gender in Spain
  • 7.6 The United Kingdom
    • 7.6.1 Prevalent cases of Sarcopenia in the UK
    • 7.6.2 Prevalence of Sarcopenia by Gender in the UK
  • 7.7 Japan
    • 7.7.1 Prevalent cases of Sarcopenia in Japan
    • 7.7.2 Prevalence of Sarcopenia by Gender in Japan

8 Treatment and Management

  • 8.1 Medical treatment directions
  • 8.2 Guidelines
    • 8.2.1 EWGSOP Guidelines
    • 8.2.2 Asian Working Group for Sarcopenia (AWGS)
    • 8.2.3 International Conference on Sarcopenia and Frailty Research (ICSFR)
  • 8.3 Selective androgen receptor modulators (SARM)
  • 8.4 Patient Journey

9 Unmet Needs

10 Appendix

  • 10.1 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables

  • Table 1: Summary of Sarcopenia Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Total cases of Sarcopenia in 7MM (2017-2030)
  • Table 3: Prevalent cases of Sarcopenia in the United States (2017-2030)
  • Table 4: Prevalence of Sarcopenia by Gender in the United States (2017-2030)
  • Table 5: Prevalent cases of Sarcopenia in Germany (2017-2030)
  • Table 6: Prevalence of Sarcopenia by Gender in Germany (2017-2030)
  • Table 7: Prevalent cases of Sarcopenia in France (2017-2030)
  • Table 8: Prevalence of Sarcopenia by Gender in France (2017-2030)
  • Table 9: Prevalent cases of Sarcopenia in Italy (2017-2030)
  • Table 10: Prevalence of Sarcopenia by Gender in Italy (2017-2030)
  • Table 11: Prevalent cases of Sarcopenia in Spain (2017-2030)
  • Table 12: Prevalence of Sarcopenia by Gender in Spain (2017-2030)
  • Table 13: Prevalent cases of Sarcopenia in the UK (2017-2030)
  • Table 14: Prevalence of Sarcopenia by Gender in the UK (2017-2030)
  • Table 15: Prevalent cases of Sarcopenia in Japan (2017-2030)
  • Table 16: Prevalence of Sarcopenia by Gender in Japan (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Criteria used to define Sarcopenia
  • Figure 3: Causes of Sarcopenia
  • Figure 4: The different pathways implicated in the pathogenesis of Sarcopenia
  • Figure 5: SARC-F Questionaire
  • Figure 6: Advantages and disadvantages of methods that can be used to measure muscle mass and strength
  • Figure 7: European Working Group of Sarcopenia in Older People
  • Figure 8: Total prevalent cases of Sarcopenia in 7MM (2017-2030)
  • Figure 9: Prevalent cases of Sarcopenia in the United States (2017-2030)
  • Figure 10: Prevalence of Sarcopenia by Gender in the United States(2017-2030)
  • Figure 11: Prevalent cases of Sarcopenia in Germany (2017-2030)
  • Figure 12: Prevalence of Sarcopenia by Gender in Germany (2017-2030)
  • Figure 13: Prevalent cases of Sarcopenia in France (2017-2030)
  • Figure 14: Prevalence of Sarcopenia by Gender in France (2017-2030)
  • Figure 15: Prevalent cases of Sarcopenia in Italy (2017-2030)
  • Figure 16: Prevalence of Sarcopenia by Gender in Italy (2017-2030)
  • Figure 17: Prevalent cases of Sarcopenia in Spain (2017-2030)
  • Figure 18: Prevalence of Sarcopenia by Gender in Spain (2017-2030)
  • Figure 19: Prevalent cases of Sarcopenia in the UK (2017-2030)
  • Figure 20: Prevalence of Sarcopenia by Gender in the UK (2017-2030)
  • Figure 21: Prevalent cases of Sarcopenia in Japan (2017-2030)
  • Figure 22: Prevalence of Sarcopenia by Gender in Japan (2017-2030)
  • Figure 23: Sarcopenia: EWGSOP2 algorithm
  • Figure 24: Sarcopenia: AWGS Guidelines
  • Figure 25: Mechanism of SARM Signaling
  • Figure 26: Patient Journey of Sarcopenia
  • Figure 27: Unmet Needs for Sarcopenia